

FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 22908-1228B	SERIAL NO. 09/903,327	CONFIRM NO. 7374
	APPLICANT NEMEROW <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 10, 2001	GROUP 1632	

RECEIVED
OCT 14 2003

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).

+ Derwent English language abstract and/or English translation provided.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	5	7	5	0	3	9	6	05/12/98	Yang et al.	435	357	05/08/95
	B	5	7	5	6	0	8	6	05/26/98	McClelland et al.	424	93.2	02/06/96
	C	5	9	2	2	5	7	6	07/13/99	He et al.	435	91.41	02/27/98
	D	5	9	3	5	9	3	5	08/10/99	Connelly et al.	514	44	06/07/95
	E	5	9	6	5	5	4	1	10/12/99	Wickham et al.	514	44	11/28/95
	F	5	9	9	4	1	2	8	11/30/99	Fallaux et al.	435	325	03/25/97
	G	5	9	9	8	2	0	5	12/07/99	Hallenbeck et al.	435	325	07/01/97
	H	6	0	3	3	9	0	8	03/07/00	Bout et al.	435	325	07/15/97
	I	6	0	5	7	1	5	5	05/02/00	Wickham et al.	435	325	08/06/98

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	J	9	4	1	7	8	3	2	08/18/94	PCT				
	K	9	5	0	0	6	5	5	01/05/95	PCT				
	L	9	5	0	2	6	9	7	01/26/95	PCT				X +
	M	9	5	0	5	2	0	1	02/23/95	PCT				
	N	9	5	1	1	9	8	4	05/04/95	PCT				
	O	9	5	2	6	4	0	9	10/05/95	PCT			X +	
	P	9	5	2	6	4	1	2	10/05/95	PCT				
	Q	9	5	2	7	0	7	1	10/12/95	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation consid red, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with n xt communication to applicant.


Title: **BIFUNCTIONAL MOLECULES AND VECTORS COMPLEXED THEREWITH FOR TARGETED GENE DELIVERY**

FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 22908-1228B	SERIAL NO. 09/903,327	CONFIRM NO. 7374
	APPLICANT NEMEROW <i>et al.</i>	CUSTOMER NO. 24961	RECEIVED OCT 14 2003 PTO CENTER 1600 2403
	FILING DATE July 10, 2001	GROUP 1632	


* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.55(d).

+ Derwent English language abstract and/or English translation provided.

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
	R	9	6	1	4	0	6	1	05/17/96	PCT				
	S	9	6	1	7	0	5	3	06/06/96	PCT				
	T	9	6	1	8	4	1	8	06/20/96	PCT				
	U	9	6	3	9	5	3	0	12/12/96	PCT				
	V	9	7	2	1	8	2	6	06/19/97	PCT				
	W	9	8	1	7	7	8	3	04/30/98	PCT				
	X	9	8	2	2	6	0	9	05/28/98	PCT				
	Y	9	8	4	4	1	2	1	10/08/98	PCT				
	Z	9	8	5	0	0	5	3	11/12/98	PCT				
	AA	9	8	5	4	3	4	6	12/03/98	PCT				
	AB	9	9	2	5	8	6	0	05/27/99	PCT				
	AC	9	9	3	6	5	4	5	07/22/99	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AD	Certified English Translation of PCT Application No. WO 95/26409, "Recombinant adenoviruses coding for basic fibroblast growth factors (bFGF)"
	AE	DERWENT #010166087, WPI Acc. No.: 1995-067340/199509 for Patent No. WO 9502697, "New defective recombinant adenovirus for gene therapy - contains inverted terminal repeats, encapsidation sequence and heterologous DNA, also cell lines able to complement the virus defect"
	AF	Gall <i>et al.</i> , "Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes", <i>J. Virol.</i> 70(4):2116-2123 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **BIFUNCTIONAL MOLECULES AND VECTORS COMPLEXED THEREWITH FOR TARGETED GENE DELIVERY**

FORM PTO-1449	ATTY. DOCKET NO. 22908-1228B	SERIAL NO. 09/903,327	CONFIRM NO. 7374
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT NEMEROW <i>et al.</i>	CUSTOMER NO. 24961	RECEIVED OCT 14 2002
	FILING DATE July 10, 2001	GROUP 1632	

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by an applicant submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.56(d).

+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AG	Mathias <i>et al.</i> , "Multiple adenovirus serotypes use α v integrins for infection" <i>J. Virol.</i> 68(10):6811-6814 (1994)
AH	Michael <i>et al.</i> , "Addition of a short peptide ligand to the adenovirus fiber protein", <i>Gene Ther.</i> 2:660-668 (1995)
AI	Roelvink <i>et al.</i> , "Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae", <i>Science</i> 286:1568-1571 (1999)
AJ	Stevenson <i>et al.</i> , "Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain", <i>J. Virol.</i> 69(5):2850-2857 (1995)
AK	Stevenson <i>et al.</i> , "Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein", <i>J. Virol.</i> 71(6):4782-4790 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **BIFUNCTIONAL MOLECULES AND VECTORS COMPLEXED THEREWITH FOR TARGETED GENE DELIVERY**